Clone:
REAL763
Type of antibody:
Releasable fluorochromes, Primary antibodies, Recombinant antibodies
Applications:
MICS, IHC, IF
Alternative names:
GLUT-1, SLC2A1, Glucose transporter type 1, HepG2 glucose transporter

Specifications for GLUT1 Antibody, anti-human, REAdye_lease™

Overview

Clone REAL763 is an antibody fragment derived from the full GLUT1 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity.
Clone REAL763 recognizes the human GLUT1 antigen, an insulin-dependent integral membrane protein that is also known as glucose transporter type 1, HepG2 glucose transporter or SLC2A1. GLUT1 is mainly found in erythrocytes and in the central nervous system and has a broad substrate specificity. Mutations in the SLC2A1 can lead to glucose transporter type 1 deficiency syndrome (GLUT1DS), which is characterised by deficient glucose transport over the blood-brain barrier and reduced glucose availability in the brain. This can lead to a wide phenotypic variability e.g. microcephaly, delayed development, epilepsy, movement disorders, and cognitive impairment.
For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675).

Alternative names

GLUT-1, SLC2A1, Glucose transporter type 1, HepG2 glucose transporter

Detailed product information

Technical specifications

CloneREAL763
Clonalitymonoclonal
Isotype controlControl Antibody
Hostcell line
Type of antibodyReleasable fluorochromes, Primary antibodies, Recombinant antibodies
Specieshuman
AntigenGLUT1
Alternative names of antigenGLUT-1, SLC2A1, Glucose transporter type 1, HepG2 glucose transporter
Distribution of antigenred blood cells, neurons

References for GLUT1 Antibody, anti-human, REAdye_lease™

Publications

  1. Schwantje, M. et al. (2020) Glucose Transporter Type 1 Deficiency Syndrome and the Ketogenic Diet Am. J. Cancer Res. 43(2): 216-222